Cytomx Therapeutics (CTMX) Stock
Clinical stage biotech developing targeted cancer treatments. Here's the price, business snapshot, and what's worth knowing about Cytomx Therapeutics in October 2026.
CytomX Therapeutics (CTMX) is a clinical‑stage biotechnology company developing conditionally activated antibody therapeutics using its Probody platform. The approach is designed to keep antibody drugs inactive in circulation and activate them within the tumour microenvironment, with the goal of widening the therapeutic window and lowering off‑tumour toxicity. Investors should be aware this is an early‑stage company: value is driven by clinical readouts, regulatory progress and potential partnerships or licensing deals rather than steady revenues. As a small‑cap stock, CytomX can be more volatile and may require additional financing to advance programmes. Key considerations for investors include trial results, cash runway, management execution and the broader oncology funding environment. This summary is for educational purposes only and not personalised investment advice; any investment could lose value and past performance is not a reliable indicator of future results.
Cytomx Therapeutics (CTMX) Stock Forecast
Analyst price target, next 12 months
$10.10
+339.1% vs today's $2.30
Price range over the last 12 months
Close to its 12-month low
Analysts covering Cytomx Therapeutics have a consensus 12-month target of $10.10, above the current price of $2.30.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 17 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CytomX Therapeutics stock with a target price of $10.1, indicating strong growth potential.
Financial Health
CytomX Therapeutics has modest revenue and cash flow, indicating a stable but limited financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Probody Activation Platform
Aims to activate antibodies at the tumour site to reduce off‑tumour effects; scientific promise carries clinical and regulatory risk, so outcomes can vary.
Event‑Driven Catalysts
Share moves often follow trial readouts, licensing deals or financing updates; these can create rapid gains or losses depending on outcomes.
Partnering & Licensing
Biotech partnerships can accelerate development and de‑risk programmes, though they depend on negotiation and regulatory progress.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
